The Use of Progesterone to Reduce Preterm Birth
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Use of Progesterone to Reduce Preterm Birth|
- Weeks Gestation at Birth Among Patients Receiving the Active Drug. [ Time Frame: Through delivery, until discharge up to 40 weeks gestation ] [ Designated as safety issue: No ]Weeks gestation at birth, the interval to delivery, or neonatal morbitity.
|Study Start Date:||June 2004|
|Study Completion Date:||June 2010|
|Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
Placebo Comparator: 1 Placebo
The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
Active Comparator: Progesterone
The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
Drug: Progesterone (OHP17)
100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
Hide Detailed Description
A. Introduction Preterm birth occurs in 7-12% of all deliveries, but accounts for over 85% of all perinatal morbidity and mortality.1 Despite many strategies for reducing the incidence of preterm birth none have been totally effective. One treatment that showed promise in earlier small trials was the prophylactic administration of progestational compounds.2,3 However, the reports of efficacy were mixed with some showing benefits4,5 while others did not.6,7 More recently, two randomized clinical trials have shown great promise8,9, and revealed a significant decrease in preterm births among women who received 17 alpha-hydroxyprogesterone caproate (17P)8, or 100mg of progesterone delivered by vaginal suppository per week.9 Indeed support by the American College of Obstetricians and Gynecologists, and March of Dimes as well as others have made this treatment the standard of care in many areas of the country.
The limitations of these studies are that they have small numbers as well as a higher than expected preterm delivery rate among placebo patients. Because of the previous controversy as to the effectiveness of progesterone noted in the 70's - 80's it is incumbent upon other centers to carry out new investigational trials in an effort to confirm their results. Secondly, the studies were limited to singleton pregnancies who were "at risk" for preterm delivery thus not surveying three groups with the highest preterm delivery rate: 1.) Multifetal gestations and cervical insufficiency; 2.) Those who have preterm labor in the current pregnancy that have been tocolyzed; 3.) Women with preterm premature rupture of the membranes.
The purpose of the current study to confirm if possible, the findings of the most recent investigations8,9 using the same patient population and in addition, we will study the effect of progesterone vs placebo in preventing early delivery among multifetal gestations in women who have been diagnosed with preterm labor in the current pregnancy.
B. Specific Aim The aim of this study is to compare progesterone (100mg progesterone weekly) to ascertain if there is a reduction in preterm birth and subsequent neonatal morbidity among patients receiving the active drug. If weekly treatment with this agent can be shown to reduce the incidence of preterm delivery and its surrogate adverse outcomes in the neonate, it will have major impact upon patients and the health care delivery system.
C. Rationale Progesterone as indicated in the Introduction has been shown in some, but not all, studies to reduce incidence of preterm delivery and the adverse effects of prematurity. Progesterone has been shown to reduce the number of oxytocin receptors in the myometrium and be responsible in the near term pregnant women for blocking the onset of labor. Weekly use of this compound, if effective, would be much superior to the tocolytic agents currently available.
D. Benefit to Risk Ratio There is no known harm to mother/fetus/infant of progesterone therapy. This compound has been used in early pregnancies at risk for abortion as well as later in pregnancy to reduce the incidence of prematurity as noted in the Introduction. On the beneficial side, if this treatment proves effective it could prolong pregnancy thus reduce significant neonatal morbidity as well as the emotional cost and expense of such pregnancies.
E. Patient Population Patients will be recruited from the University of Mississippi Medical Center Perinatal Clinics, Antepartum Service and Labor and Delivery area. All patients who meet admission criteria will be offered participation in the study.
F. Materials and Methods Patients seen in the University of Mississippi Perinatal Clinics, Antepartum ward or Labor and Delivery area with preterm labor or who are at risk for preterm labor and who meet other admission criteria (without having exclusion criteria) will be offered participation of this study.
Study Protocol Patients meeting the inclusion criteria will have the study explained to them, including benefits risks and alternative therapy. Patients not desiring to participate in the study will receive our current regimen of preterm birth prevention (observation, risk factor assessment, steroids, progesterone, etc). If they accept inclusion into the study after the above explanation they will be randomized by the use of sequentially numbered, sealed opaque envelopes to either receive progesterone or a placebo injection on a weekly basis. Patients with risk factors for preterm birth (prior preterm birth) will be separately randomized from the multifetal gestations or cervical cerclage and the patients with preterm labor in the current pregnancy as well as preterm rupture of the membranes will also separately randomized (four groups total). Neither patients nor participants will know to which group (placebo vs. progesterone) they are assigned as the pharmacy will keep the randomization schedule and will dispense the two solutions in identical syringes for blinding purposes.
Treatment will begin at different gestational ages dependent upon the four groups noted above. For example, multifetal gestation due to their incidence of labor at earlier gestational ages, will begin treatment at 20 weeks' gestation. Those in the preterm labor with the current pregnancy group or premature rupture of membranes will begin their therapy after admission to the hospital following stabilization. All patients will stop therapy at 34 completed weeks of gestation.
After inclusion into the study, prenatal care will be exactly the same as is our standard for such patients at risk for early delivery with the exception of the weekly administration of the study medicine or placebo. For example, weekly prenatal visits, cervical examinations, ultrasounds, steroids and/or tocolytic treatment (given when preterm labor is diagnosed) will be the same regardless of the group to which the patient is randomized. All groups will have one tube of blood drawn from the placental cord at the time of delivery. There will be no additional visits or costs due to the study itself.
F. Data Analysis Data analysis will be by the standard statistical methodology.
VI. Number of Patients Needed:
A sample size estimation indicates that 320 patients (40 in each of four groups-treatment and placebo) will be necessary to have an 80% power of detecting a significance of < 0.05 in the number of preterm births. It is anticipated that a time period of approximately two years will be needed to enroll this number of participants.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00830765
|United States, Mississippi|
|Winfred L Wiser Hospital for Women and Infants at the University of Mississippi Medical Center|
|Jackson, Mississippi, United States, 39216|
|Principal Investigator:||John C Morrison, MD||University of Mississippi Medical Center|